ブリギマドリンによる以前の研究に参加した固形腫瘍患者におけるブリギマドリンによる長期治療を試験する研究
固形腫瘍患者を対象とした経口ブリギマドリンの第II相、単群、非盲検、長期安全性ロールオーバー試験
This study is open to adults with solid tumours who received at least 4 cycles of treatment with brigimadlin in a previous study. The goal of this study is to find out how well people with solid tumours tolerate long-term treatment with brigimadlin. Brigimadlin is a so-called MDM2 inhibitor that was being developed to treat cancer.
All participants take brigimadlin as tablets once every 3 weeks at the study site. At study visits, doctors check participants' health and take note of any unwanted effects. At some study visits, doctors also check the size of the tumour and whether it has spread to other parts of the body. Participants are in the study as long as they benefit from treatment and can tolerate it.
調査の概要
研究の種類
入学 (実際)
段階
- フェーズ2
連絡先と場所
研究場所
-
-
California
-
Beverly Hills、California、アメリカ、90212
- Precision NextGen Oncology
-
Santa Monica、California、アメリカ、90403
- Sarcoma Oncology Center
-
-
Connecticut
-
New Haven、Connecticut、アメリカ、06511
- Yale Cancer Center
-
-
Florida
-
Jacksonville、Florida、アメリカ、32224
- Mayo Clinic Cancer Center
-
-
Missouri
-
St Louis、Missouri、アメリカ、63108
- Washington University School of Medicine
-
-
Nebraska
-
Omaha、Nebraska、アメリカ、68130
- Nebraska Cancer Specialists-Omaha-69066
-
-
New York
-
Lake Success、New York、アメリカ、11042
- Northwell Health
-
-
Tennessee
-
Germantown、Tennessee、アメリカ、38138
- West Cancer Center & Research Institute
-
Nashville、Tennessee、アメリカ、37232
- Henry-Joyce Cancer Clinic
-
-
Texas
-
Houston、Texas、アメリカ、77030
- The University of Texas MD Anderson Cancer Center
-
-
Utah
-
Salt Lake City、Utah、アメリカ、84106
- Utah Cancer Specialists Cancer Center
-
-
Washington
-
Seattle、Washington、アメリカ、98109
- Fred Hutchinson Cancer Research Center
-
-
Wisconsin
-
Madison、Wisconsin、アメリカ、53792
- University of Wisconsin
-
-
-
-
-
CABA、アルゼンチン、C1120AAB
- Sanatorio Finochietto
-
-
-
-
-
Cambridge、イギリス、CB2 0QQ
- Addenbrooke's Hospital
-
London、イギリス、SW3 6JJ
- The Royal Marsden Hospital, Chelsea
-
London、イギリス、NW12PQ
- University College Hospital
-
-
-
-
-
Tel Aviv、イスラエル、6423906
- Sourasky Medical Center
-
-
-
-
-
Milan、イタリア、20133
- Fondazione IRCCS Istituto Nazionale dei Tumori
-
Padova、イタリア、35128
- Istituto Oncologico Veneto IRCCS
-
-
-
-
New South Wales
-
Randwick、New South Wales、オーストラリア、2031
- Prince of Wales Hospital-Randwick-66496
-
-
Queensland
-
Woolloongabba、Queensland、オーストラリア、4102
- Princess Alexandra Hospital
-
-
-
-
Alberta
-
Calgary、Alberta、カナダ、T2N 5G2
- Arthur J. E. Child Comprehensive Cancer Centre
-
-
Ontario
-
Toronto、Ontario、カナダ、M5G 2M9
- Princess Margaret Cancer Centre
-
-
-
-
-
Stockholm、スウェーデン、SE-171 76
- Karolinska Comprehensive Cancer Center
-
-
-
-
-
Aragon、スペイン、50009
- Hospital Universitario Miguel Servet
-
Madrid、スペイン、28040
- Fundación Jiménez Díaz
-
Madrid、スペイン、28041
- Hospital Universitario 12 de Octubre
-
Madrid、スペイン、28050
- Hospital Universitario HM Sanchinarro
-
Santiago de Compostela、スペイン、15706
- Hospital Clínico de Santiago
-
-
-
-
-
Olomouc、チェコ、77900
- University Hospital Olomouc
-
-
-
-
-
København Ø、デンマーク、2100
- Copenhagen University Hospital, Rigshospitalet
-
-
-
-
-
Berlin、ドイツ、13125
- Helios Klinikum Berlin-Buch
-
Tübingen、ドイツ、72076
- Universitätsklinikum Tübingen
-
-
-
-
-
Oslo、ノルウェー、N-0379
- Oslo Universitetssykehus HF, Radiumhospitalet
-
-
-
-
-
Gyöngyös、ハンガリー、3200
- Clinexpert Gyongyos
-
-
-
-
-
Lyon、フランス、69373
- CTR Leon Berard
-
Rennes、フランス、35042
- CTR Eugène Marquis
-
-
-
-
-
Brussels、ベルギー、1200
- Cliniques Universitaires Saint-Luc
-
Leuven、ベルギー、3000
- UZ Leuven
-
-
-
-
-
Warsaw、ポーランド、02-781
- Oncology Center-Maria Sklodowska-Curie Institute
-
-
-
-
-
Guangzhou、中国、510060
- Sun Yat-Sen University Cancer Center
-
-
-
-
-
Taipei、台湾、11217
- Taipei Veterans General Hospital
-
-
-
-
-
Fukuoka, Fukuoka、日本、812-8582
- Kyushu University Hospital
-
Fukuoka, Fukuoka、日本、811-1395
- National Hospital Organization Kyushu Cancer Center
-
Kanagawa, Yokohama、日本、241-8515
- Kanagawa Cancer Center
-
Miyagi, Sendai、日本、980-8574
- Tohoku University Hospital
-
Okayama, Okayama、日本、700-8558
- Okayama University Hospital
-
Osaka, Osaka、日本、541-8567
- Osaka International Cancer Institute
-
Tokyo, Chuo-ku、日本、104-0045
- National Cancer Center Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion criteria:
- Patient is ongoing on brigimadlin treatment in any trial sponsored by Boehringer Ingelheim (hereafter referred to as the 'parent trial').
- Provision of signed and dated, written informed consent form (ICF) in accordance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use - Good Clinical Practice (ICH-GCP) and local legislation prior to any trial-specific procedures, sampling, or analyses.
- Women of childbearing potential (WOCBP) and men able to father a child must be ready and able to use 2 medically acceptable methods of birth control per ICH M3 (R2) that result in a low failure rate of <1% per year when used consistently and correctly beginning at Screening, during trial participation, and until 6 months and 12 days after the last dose for women and 102 days after the last dose for men. A list of contraception methods meeting these criteria and instructions on the duration of use is provided in the participant information.
- Participants must be willing and able to comply with the scheduled visits, treatment plan, lifestyle, laboratory tests, contraceptive guidelines, and other study procedures.
- Adequate organ function.
- Patient is eligible to receive continued treatment according to the clinical trial protocol of the parent trial they are currently participating in. Patients currently experiencing a dose delay in the parent trial due to adverse events are eligible if recovery from the adverse event takes place within the allowed time window in the parent trial.
Exclusion criteria:
- Any medical condition which in the opinion of the investigator should exclude the patient from receiving treatment with brigimadlin.
- Participants who must receive or intend to receive restricted medications or any drug considered likely to interfere with the safe conduct of the trial.
- Women who are pregnant, nursing, or who plan to become pregnant while in the trial. Female patients who do not agree to the interruption of breastfeeding from the start of study treatment until 6 months and 12 days after the last dose of study treatment.
- Patient has unacceptable toxicity on brigimadlin at the time of transition into this trial.
- Patient has an adverse event (AE) which has caused a dose delay and has not recovered within the allowed time window in the parent trial.
- Patient who has already required 2 dose reductions and would require a third dose reduction at trial entry, unless the investigator deems treatment continuation beneficial, and the third dose reduction is agreed in writing between the investigator and the sponsor.
Further exclusion criteria apply.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:ブリギマドリン
|
Brigimadlin
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
The primary endpoint will be the occurrence of treatment-emergent adverse events (AEs) according to CTCAE Version 5.0 during the entire treatment period
時間枠:up to 9 years.
|
CTCAE=Common Terminology Criteria for Adverse Events |
up to 9 years.
|
協力者と研究者
スポンサー
出版物と役立つリンク
便利なリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 1403-0032
- 2024-514177-21-00 (レジストリ識別子:CTIS)
- U1111-1305-3484 (レジストリ識別子:WHO International Clinical Trials Registry Platform (ICTRP))
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Once the criteria in section 'time frame' are fulfilled, researchers can use the following link https:// www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.
IPD 共有時間枠
One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.
IPD 共有アクセス基準
For study documents -upon signing of a 'Document Sharing Agreement'. For study data -1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
- CSR
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。